ArticleProgress in orthodontics2021
Sexual dimorphism in the long-term stability (10 years) of skeletal Class III treatment.
Article in Progress in orthodontics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 4 citations in OpenAlex.
- Morphological variations and differences of the mandible and midfacial skeleton across different sagittal skeletal patterns and sexes: a three-dimensional geometric morphometric analysis.Progress in orthodontics · 2026Article
- Analysis of predictive factors for post-orthodontic stability: a retrospective cohort study.BMC oral health · 2026Article
- Anterior Tooth Inclination Between Skeletal Class II and III Malocclusions After Surgical Orthodontic Treatment.Diagnostics (Basel, Switzerland) · 2025Article
- Maxillofacial growth changes after maxillary protraction therapy in children with class III malocclusion: a dual control group retrospective study.BMC oral health · 2024Article
- Prediction Model for Future Success of Early Orthopedic Treatment of Class III Malocclusion.Children (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClass III malocclusion is associated with high sexual dimorphism, especially in individuals older than 13 years of age, with significant differences in growth between males and females during the pubertal and postpubertal stages, and in adulthood. The aim of this research was to examine differences between males and females in long-term stability (10 years) of treatment for skeletal Class III malocclusion.
methodsThirty patients (15 males and 15 females) with skeletal Class III malocclusion, who had been treated with rapid maxillary expansion (RME) combined with face mask protraction followed by fixed appliances, were selected sequentially. Thirty patients (15 males and 15 females) with skeletal Class I and mesofacial patterns treated only with fixed appliances for dental problems served as the control group. Differences between groups and sexes were evaluated using lateral cephalograms taken at the start of treatment (T0), immediately after the end of treatment (T1), and after 10 years (T2). The long-term treatment success rate was calculated.
resultsTen years after Class III treatment, overjet and overbite relapse occurred similarly in females (- 0.68 ± 0.7 mm; - 0.38 ± 0.75 mm, respectively) and males (- 1.09 ± 1.47 mm; - 0.64 ± 0.9 mm, respectively); the ANB angle and Wits appraisal became significantly more negative in males (- 1.37 ± 1.06°; - 2.7 ± 2.53 mm) than in females (- 0.18 ± 1.26°; - 0.46 ± 1.94 mm). The success rate was 73.3% in males and 80% in females.
conclusionsSignificant differences in the long-term stability of Class III treatment outcomes have been found between males and females, with a larger skeletal Class III relapse and lower long-term success rates in males.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.